Onconetix, Inc. (ONCO)

Market Cap	2.99M +85.1%
Revenue (ttm)	645,824 -51.3%
Net Income	-9.03M
EPS	-15.19
Shares Out	3.69M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	236,760
Open	0.8800
Previous Close	0.8824
Day's Range	0.8113 - 0.8800
52-Week Range	0.6652 - 209.5000
Beta	2.69
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 13, 2026

About ONCO

Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men’s health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. It has a license agreement with LabCorp to develop and commercialize Proclarix and other products; and with Immunovia AB for the development, manufacturing, and commercialization of the PancreaSure test. The company was formerly known as Bl...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Feb 18, 2022
• Employees: 2
• Stock Exchange: NASDAQ
• Ticker Symbol: ONCO
• Website: https://www.onconetix.com

Financial Performance

In 2025, Onconetix's revenue was $815,371, a decrease of -67.70% compared to the previous year's $2.52 million. Losses were -$15.53 million, -73.63% less than in 2024.

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Aug 15, 2026

Data Sources Report a data error